Benefits
Common Cold Treatment (Cold-Eeze)
Zinc acetate lozenges (Cold-Eeze) reduce cold duration when started within 24 hours of symptoms. Some Hemilä meta-analyses suggest zinc acetate may have slight edge over gluconate (more zinc ion release at saliva pH).
Wilson's Disease Treatment (PHARMACEUTICAL)
Zinc acetate (Galzin®) is FDA-approved for Wilson's disease — a genetic disorder of copper metabolism causing copper accumulation in liver, brain, and other organs. High-dose zinc acetate (50 mg elemental zinc TID) induces metallothionein in intestinal cells, sequestering dietary copper and preventing absorption. Prescription only; requires hepatology supervision.
Bioavailability
Zinc acetate is well-absorbed — among the well-bioavailable forms. Releases zinc ions readily at saliva and gastric pH.
Standard Zinc Benefits
Same general zinc benefits as other forms — immune support, skin/wound healing, growth/development, taste/smell, antioxidant function.
Reasonable Cost
Zinc acetate is cost-comparable to gluconate; a reasonable choice for both supplementation and lozenge applications.
Mechanism of action
Zinc Ion Release at Throat pH
Hemilä's research suggests zinc acetate releases more zinc ions in saliva than zinc gluconate — basis for slight cold-treatment advantage. The clinically relevant variable is total Zn²⁺ concentration in throat mucosa during lozenge dissolution.
Wilson's Disease Mechanism (Metallothionein Induction)
High-dose oral zinc acetate induces METALLOTHIONEIN in enterocytes — a small protein that binds and sequesters copper. Dietary copper binds metallothionein, fails to absorb, and is shed with intestinal epithelial cells into stool. Effective copper elimination strategy.
Acetic Acid Release
Acetic acid (vinegar) is well-tolerated and rapidly metabolized to acetyl-CoA — innocuous at supplemental amounts.
Standard Zinc Enzyme Functions
Same as other zinc forms — >300 enzyme cofactor, zinc finger transcription factors, antioxidant via Cu/Zn-SOD.
Clinical trials
Subgroup analyses within Hemilä Cochrane meta-analyses comparing zinc acetate vs zinc gluconate lozenges for cold duration.
Pooled across cold lozenge RCTs.
Both forms reduce cold duration vs placebo; zinc acetate may have modest edge over gluconate (~40% vs ~28% duration reduction). Both effective when started within 24 hours.
Trials of zinc acetate (50 mg elemental zinc TID) in Wilson's disease patients for maintenance therapy after initial chelation.
Wilson's disease patients.
Zinc acetate effectively maintains negative copper balance in Wilson's disease — induces intestinal metallothionein blocking copper absorption. FDA-approved (Galzin®) for Wilson's. Prescription pharmaceutical use.